

Use these questions as thought starters to discuss with your doctor as you prepare for your first RYBREVANT[®] infusions. They are an easy way to get organized and be informed.

- 1 How is RYBREVANT[®] administered, and how frequently?
- 2 How long will my first infusion last? Will all infusions take the same amount of time?
- 3 Where do infusions take place?
- 4 What is an infusion-related reaction?
- 5 How will I know if I'm experiencing an infusion-related reaction?
- 6 How quickly could I experience an infusion-related reaction? How long do they last?
- 7 What can I do to reduce the chances of an infusion-related reaction?
- 8 What other possible side effects may I experience?
- 9 What can I do to reduce the chances of experiencing possible side effects?
- 10 Are there resources and support programs available to me as I start RYBREVANT[®]?

Informative conversations with your doctor are an important part of the treatment journey. Be sure to ask your doctor any other questions you may have.

What is RYBREVANT[®] (amivantamab-vmjw)?

RYBREVANT[®] is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE™ (lazertinib), a prescription medicine, as a first-line treatment for non-small cell lung cancer (NSCLC)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT[®] or RYBREVANT[®] in combination with LAZCLUZE™ is right for you.

It is not known if RYBREVANT[®] or LAZCLUZE™ is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT[®] as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of lung or breathing problems.
- are pregnant or plan to become pregnant. RYBREVANT[®] and LAZCLUZE™ can harm your unborn baby.

Females who are able to become pregnant:

- o Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT[®] or RYBREVANT[®] in combination with LAZCLUZE™.

Please read the continued Important Safety Information for RYBREVANT[®] on the next page.

IMPORTANT SAFETY INFORMATION (cont'd)

- You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT[®].
- For patients receiving LAZCLUZE™: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT[®] or LAZCLUZE™.

Males who have female partners who are able to become pregnant:

- You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT[®] passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT[®]. It is not known if LAZCLUZE™ passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE™.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

LAZCLUZE™ may affect the way other medicines work, and other medicines may affect how LAZCLUZE™ works. You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE™.

How will I receive RYBREVANT[®]?

- RYBREVANT[®] will be given to you by your healthcare provider by intravenous infusion into your vein.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of RYBREVANT[®] to help reduce the risk of infusion-related reactions.
- RYBREVANT[®] may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
- If your treatment with RYBREVANT[®] is given in combination with LAZCLUZE™ (lazertinib), you should take your dose of LAZCLUZE™ by mouth anytime before your infusion with RYBREVANT[®].
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

How should I take LAZCLUZE™?

- Take LAZCLUZE™ exactly as your healthcare provider tells you to take it.
- Take LAZCLUZE™ one (1) time each day. On the day RYBREVANT[®] is also given, take LAZCLUZE™ any time before receiving the RYBREVANT[®] infusion.
- You can take LAZCLUZE™ with or without food.
- Swallow LAZCLUZE™ tablets whole. **Do not** crush, cut, or chew the tablets.
- If you miss a dose of LAZCLUZE™ and:
 - it has been **less than** 12 hours, take the missed dose.
 - it has been **more than** 12 hours, skip the dose and take your next dose at your regularly scheduled time.

- If you vomit a dose of LAZCLUZE™, do not take an extra dose. Take your next dose at your regularly scheduled time.
- LAZCLUZE™ may be given in combination with other anti-cancer medicines. If you have any questions about these medicines, ask your healthcare provider.

What should I avoid while receiving RYBREVANT[®] and/or LAZCLUZE™?

RYBREVANT[®] and RYBREVANT[®] in combination with LAZCLUZE™ can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT[®] and/or LAZCLUZE™. Wear protective clothing and use sunscreen during treatment with RYBREVANT[®] and/or LAZCLUZE™.

What are the possible side effects of RYBREVANT[®] or LAZCLUZE™?

RYBREVANT[®] and LAZCLUZE™ may cause serious side effects, including:

- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT[®] and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT[®]:

○ shortness of breath	○ flushing
○ fever	○ chest discomfort
○ chills	○ lightheadedness
○ nausea	○ vomiting
- **lung problems.** RYBREVANT[®] may cause lung problems that may lead to death. LAZCLUZE™ may also cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** Blood clots are a serious, but common side effect of RYBREVANT[®], when given together with LAZCLUZE™, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT[®] can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. LAZCLUZE™ may cause severe rash including redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT[®] or LAZCLUZE™. See "What should I avoid while receiving RYBREVANT[®] and/or LAZCLUZE™?"
- **eye problems.** RYBREVANT[®] may cause eye problems. LAZCLUZE™ may also cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:

Please read the continued Important Safety Information for RYBREVANT[®] on the next page.

IMPORTANT SAFETY INFORMATION (cont'd)

- o eye pain
- o inflammation of eye lids
- o inflamed cornea (front part of the eye)
- o dry eyes
- o eye redness
- o blurred vision
- o changes in vision
- o itchy eyes
- o excessive tearing
- o sensitivity to light
- o new or worsening problems with vision

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT® or LAZCLUZE™. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects of RYBREVANT® in combination with LAZCLUZE™ (lazertinib) include:

- rash
- infected skin around the nail
- muscle and joint pain
- sores in the mouth
- swelling of hands, ankles, feet, face, or all of your body
- unusual feeling in the skin (such as tingling or a crawling feeling)
- feeling very tired
- diarrhea
- constipation
- COVID-19
- dry skin
- bleeding
- decreased appetite
- itchy skin
- nausea
- changes in certain blood tests

The most common side effects of RYBREVANT® in combination with carboplatin and pemetrexed include:

- rash
- infected skin around the nail
- sores in the mouth
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- constipation
- decreased appetite
- nausea
- COVID-19
- diarrhea
- vomiting
- changes in certain blood tests

The most common side effects of RYBREVANT® when given alone:

- rash
- infected skin around the nail
- muscle and joint pain
- shortness of breath
- nausea
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- sores in the mouth
- cough
- constipation
- vomiting
- changes in certain blood tests

LAZCLUZE™ may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT® or LAZCLUZE™ if you have serious side effects.

These are not all of the possible side effects of RYBREVANT® or LAZCLUZE™.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your healthcare provider or pharmacist for information about RYBREVANT® that is written for health professionals.

General information about the safe and effective use of LAZCLUZE™:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LAZCLUZE™ for a condition for which it was not prescribed. Do not give LAZCLUZE™ to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about LAZCLUZE™ that is written for health professionals.

Please read full [Prescribing Information](#) for RYBREVANT®.
Please read full [Prescribing Information](#) for LAZCLUZE™.

cp-213277v5